keyword
MENU ▼
Read by QxMD icon Read
search

Cardio-oncology

keyword
https://www.readbyqxmd.com/read/29355045/cardio-oncology-an-evolving-hybrid-subspecialty
#1
Carol Chen-Scarabelli, William G Hundley, Tiziano M Scarabelli
No abstract text is available yet for this article.
January 22, 2018: Future Cardiology
https://www.readbyqxmd.com/read/29251671/heart-failure-following-oncological-treatment
#2
James Marangou, Andrew Redfern, Tony Haddad, James M Rankin, Girish Dwivedi
PURPOSE OF REVIEW: The aim of this review is to give the reader an up-to-date overview of the progress made in the burgeoning field of cardio-oncology, encompassing oncological treatments conferring risk, prediction strategies to identify patients at risk, imaging and biomarker monitoring for emergent or subclinical toxicity and prevention in primary and secondary settings with a focus on heart failure. RECENT FINDINGS: The rapid recent advances in cancer management, particularly with the expansion of targeted and immunotherapies, have led to substantial improvements in outcome, but have also added to the potential causes of cardiac toxicity, which can lead to heart failure...
December 14, 2017: Current Opinion in Cardiology
https://www.readbyqxmd.com/read/29217664/incidence-diagnosis-and-management-of-qt-prolongation-induced-by-cancer-therapies-a-systematic-review
#3
REVIEW
Andreu Porta-Sánchez, Cameron Gilbert, Danna Spears, Eitan Amir, Joyce Chan, Kumaraswamy Nanthakumar, Paaladinesh Thavendiranathan
BACKGROUND: The cardiovascular complications of cancer therapeutics are the focus of the burgeoning field of cardio-oncology. A common challenge in this field is the impact of cancer drugs on cardiac repolarization (ie, QT prolongation) and the potential risk for the life-threatening arrhythmia torsades de pointes. Although QT prolongation is not a perfect marker of arrhythmia risk, this has become a primary safety metric among oncologists. Cardiologists caring for patients receiving cancer treatment should become familiar with the drugs associated with QT prolongation, its incidence, and appropriate management strategies to provide meaningful consultation in this complex clinical scenario...
December 7, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/29211884/impact-of-current-and-past-cancer-history-on-the-risk-of-cardiovascular-events-following-percutaneous-coronary-intervention-a-kumamoto-university-malignancy-and-atherosclerosis-kuma-study
#4
Noriaki Tabata, Daisuke Sueta, Eiichiro Yamamoto, Seiji Takashio, Yuichiro Arima, Satoshi Araki, Kenshi Yamanaga, Masanobu Ishii, Kenji Sakamoto, Hisanori Kanazawa, Koichiro Fujisue, Shinsuke Hanatani, Hirofumi Soejima, Seiji Hokimoto, Yasuhiro Izumiya, Sunao Kojima, Hiroshige Yamabe, Koichi Kaikita, Kenichi Tsujita
Background: As progress is made in successfully treating cancer, there is increasing need to focus on the risk and complexity of treating cardiovascular events in cancer survivors - thus, the field of onco-cardiology/cardio-oncology has emerged. We examined the differential incidence of cardiovascular events after percutaneous coronary intervention (PCI) in patients with or without cancer. Methods and Results: Participants were divided into a non-cancer group and a cancer group, which consisted of patients who were receiving or had ever received cancer treatment...
December 1, 2017: European Heart Journal. Quality of Care & Clinical Outcomes
https://www.readbyqxmd.com/read/29208517/selection-of-the-best-of-2017-on-cardio-oncology-what-should-we-know
#5
Teresa López-Fernández, Ana Martin-García, Sonia Velasco Del Castillo, Cristina Mitroi
No abstract text is available yet for this article.
December 2, 2017: Revista Española de Cardiología
https://www.readbyqxmd.com/read/29203166/current-status-of-cardio-oncology-in-spain-a-national-multidisciplinary-survey
#6
Ana Martín-García, Cristina Mitroi, Ramón García Sanz, Ana Santaballa Bertrán, Meritxell Arenas, Teresa López-Fernández
No abstract text is available yet for this article.
December 1, 2017: Revista Española de Cardiología
https://www.readbyqxmd.com/read/29201269/cardiac-nonmyocyte-cell-functions-and-crosstalks-in-response-to-cardiotoxic-drugs
#7
REVIEW
Jessica Gambardella, Bruno Trimarco, Guido Iaccarino, Daniela Sorriento
The discovery of the molecular mechanisms involved in the cardiac responses to anticancer drugs represents the current goal of cardio-oncology research. The oxidative stress has a pivotal role in cardiotoxic responses, affecting the function of all types of cardiac cells, and their functional crosstalks. Generally, cardiomyocytes are the main target of research studies on cardiotoxicity, but recently the contribution of the other nonmyocyte cardiac cells is becoming of growing interest. This review deals with the role of oxidative stress, induced by anticancer drugs, in cardiac nonmyocyte cells (fibroblasts, vascular cells, and immune cells)...
2017: Oxidative Medicine and Cellular Longevity
https://www.readbyqxmd.com/read/29172746/pazopanib-for-renal-cell-carcinoma-leads-to-elevated-mean-arterial-pressures-in-a-murine-model
#8
Amber Kempton, Cody Justice, Aaron Guo, Matthew Cefalu, Michael Makara, Paul Janssen, Thai H Ho, Sakima A Smith
BACKGROUND: In the setting of metastatic RCC (mRCC), pazopanib is approved as first line therapy. Unfortunately treatment may lead to cardiotoxicity such as hypertension, heart failure, and myocardial ischemia. OBJECTIVE: Define the in vivo role of pazopanib in the development of cardiotoxicity. METHODS: Wild type mice were dosed for 42 days via oral gavage, and separated into control and treatment (pazopanib) groups. Baseline ECG's, echocardiograms, and blood pressures were recorded...
November 27, 2017: Clinical and Experimental Hypertension: CHE
https://www.readbyqxmd.com/read/29158212/cardiac-toxicity-of-immune-checkpoint-inhibitors-cardio-oncology-meets-immunology
#9
Gilda Varricchi, Maria Rosaria Galdiero, Carlo G Tocchetti
No abstract text is available yet for this article.
November 21, 2017: Circulation
https://www.readbyqxmd.com/read/29135296/-ischaemic-heart-disease-in-cancer-patients-questions-and-problems
#10
Petra Gulácsi-Bárdos, Miklós Szokol, Mária Lódi, Dániel Czuriga, István Czuriga, István Édes, András Nagy, Balázs Sármán
Cardiovascular and oncologic diseases are the causes of more than 50 percent of mortality in Europe. In 2015 oncologic and cardiovascular mortality reached 70 percent in Hungary. Patients who receive anticancer therapies are at a 2- to 7-fold greater long-term risk of acute coronary syndrome; also concomittant oncologic diseases further increase the mortality of myocardial infarction. Unfortunately there is not enough data concerning cardiovascular treatment of oncologic patients because they were excluded from most of the studies and registries...
October 2017: Orvosi Hetilap
https://www.readbyqxmd.com/read/29119374/review-of-cardiovascular-imaging-in-the-journal-of-nuclear-cardiology-2017-part-1-of-2-positron-emission-tomography-computed-tomography-and-magnetic-resonance
#11
Wael A AlJaroudi, Fadi G Hage
Several original articles and editorials have been published in the Journal of Nuclear Cardiology in 2017. It has become a tradition at the beginning of each year to summarize some of these key articles in 2 sister reviews. In this first part one, we will discuss some of the progress made in the field of heart failure (cardio-oncology, myocardial blood flow, viability, dyssynchrony, and risk stratification), inflammation, molecular and hybrid imaging using advancement in positron emission tomography, computed tomography, and magnetic resonance imaging...
November 8, 2017: Journal of Nuclear Cardiology: Official Publication of the American Society of Nuclear Cardiology
https://www.readbyqxmd.com/read/29111106/2017-comprehensive-update-of-the-canadian-cardiovascular-society-guidelines-for-the-management-of-heart-failure
#12
Justin A Ezekowitz, Eileen O'Meara, Michael A McDonald, Howard Abrams, Michael Chan, Anique Ducharme, Nadia Giannetti, Adam Grzeslo, Peter G Hamilton, George A Heckman, Jonathan G Howlett, Sheri L Koshman, Serge Lepage, Robert S McKelvie, Gordon W Moe, Miroslaw Rajda, Elizabeth Swiggum, Sean A Virani, Shelley Zieroth, Abdul Al-Hesayen, Alain Cohen-Solal, Michel D'Astous, Sabe De, Estrellita Estrella-Holder, Stephen Fremes, Lee Green, Haissam Haddad, Karen Harkness, Adrian F Hernandez, Simon Kouz, Marie-Hélène LeBlanc, Frederick A Masoudi, Heather J Ross, Andre Roussin, Bruce Sussex
Since the inception of the Canadian Cardiovascular Society heart failure (HF) guidelines in 2006, much has changed in the care for patients with HF. Over the past decade, the HF Guidelines Committee has published regular updates. However, because of the major changes that have occurred, the Guidelines Committee believes that a comprehensive reassessment of the HF management recommendations is presently needed, with a view to producing a full and complete set of updated guidelines. The primary and secondary Canadian Cardiovascular Society HF panel members as well as external experts have reviewed clinically relevant literature to provide guidance for the practicing clinician...
November 2017: Canadian Journal of Cardiology
https://www.readbyqxmd.com/read/29105670/-application-of-a-shared-interdisciplinary-and-multiprofessional-cardio-oncology-in-hospital-pathway
#13
Maria Laura Canale, Andrea Camerini, Massimo Magnacca, Jacopo Del Meglio, Alessio Lilli, Sara Donati, Lucia Belli, Stefania Lencioni, Domenico Amoroso, Giancarlo Casolo
The burden of cardiac side effects in oncology patients will dramatically increase in the near future as a result of the widespread use of anticancer agents affecting the cardiovascular system, the general population aging, the heightened attention in the detection of cardiac toxicity and the absolute gain in terms of overall survival. The relationship between cardiologists and oncologists should therefore be closer leading to the definition of cardio-oncology. The increased number of such patients requires the creation of a dedicated patient assistance program in order to guarantee every patient the possibility of an interdisciplinary and multiprofessional approach...
November 2017: Giornale Italiano di Cardiologia
https://www.readbyqxmd.com/read/29087234/cardio-oncology-in-multiple-myeloma-is-it-time-for-a-specific-focus
#14
Salvatrice Mancuso, Melania Carlisi, Matteo Sarocchi, Mariasanta Napolitano, Sergio Siragusa
No abstract text is available yet for this article.
October 31, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28941563/the-role-of-cardio-oncology-in-the-interprofessional-care-of-adult-patients-receiving-cancer-therapy
#15
REVIEW
Edith Pituskin, Ian Paterson, Nanette Cox-Kennett, Derek Rothe, Melissa Perri, Harald Becher
OBJECTIVE: To discuss the toxic effects of therapy to the structure and function of the cardiovascular system and the role of the cardio-oncology team in the interprofessional care of adult patients, including current approaches, research findings, and future endeavors DATA SOURCE: Published articles and international cardiology and oncology association guidance documents. CONCLUSION: Although a new field of study, cardio-oncology is a rapidly expanding area of great clinical need...
November 2017: Seminars in Oncology Nursing
https://www.readbyqxmd.com/read/28934410/approach-to-cardio-oncologic-patients-with-special-focus-on-patients-with-cardiac-implantable-electronic-devices-planned-for-radiotherapy-results-of-the-european-heart-rhythm-association-survey
#16
Radoslaw Lenarczyk, Tatjana S Potpara, Kristina H Haugaa, Jean-Claude Deharo, Antonio Hernandez-Madrid, Maria Del Carmen Exposito Pineda, Marek Kiliszek, Nikolaos Dagres
The aim of this European Heart Rhythm Association (EHRA) survey was to evaluate clinical practice regarding cardio-oncologic patients, with special focus on patients with cardiac implantable electronic devices (CIEDs) planned for anticancer radiotherapy (RT), among members of the EHRA electrophysiology research network. Of the 36 responding centres, 89% managed patients who were diagnosed or treated oncologically, and this diagnosis affected 1-5% of cardiovascular patients in majority of centres (57%). The main side effects of anticancer therapy in patients treated by cardiologists were thromboembolic complications and left ventricular dysfunction (both reported as 'frequent' by 43% of the centres)...
September 1, 2017: Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology
https://www.readbyqxmd.com/read/28929270/mode-of-treatment-governs-curcumin-response-on-doxorubicin-induced-toxicity-in-cardiomyoblasts
#17
Aditi Jain, Vibha Rani
Doxorubicin (Dox) is an effective anti-cancer drug with severe reported cardiotoxicity. Cardiovascular risks associated with present cancer therapeutics demand urgent attention. There has been a growing interest in naturally occurring compounds to improve the therapeutic index as well as prevent non-tumour tissues from sustaining chemotherapy-induced damages. In the present study, the effects of curcumin, a polyphenol isolated from Curcuma longa and well known for its anti-oxidative, anti-cancerous and anti-inflammatory properties, was studied in relation to the Dox-induced cardiotoxicity...
September 19, 2017: Molecular and Cellular Biochemistry
https://www.readbyqxmd.com/read/28911261/out-of-the-frying-pan-and-into-the-fire-damage-associated-molecular-patterns-and-cardiovascular-toxicity-following-cancer-therapy
#18
REVIEW
Nicole S Klee, Cameron G McCarthy, Patricia Martinez-Quinones, R Clinton Webb
Cardio-oncology is a new and rapidly expanding field that merges cancer and cardiovascular disease. Cardiovascular disease is an omnipresent side effect of cancer therapy; in fact, it is the second leading cause of death in cancer survivors after recurrent cancer. It has been well documented that many cancer chemotherapeutic agents cause cardiovascular toxicity. Nonetheless, the underlying cause of cancer therapy-induced cardiovascular toxicity is largely unknown. In this review, we discuss the potential role of damage-associated molecular patterns (DAMPs) as an underlying contributor to cancer therapy-induced cardiovascular toxicity...
November 2017: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/28862931/cardiovascular-adverse-events-in-patients-with-cancer-treated-with-bevacizumab-a-meta-analysis-of-more-than-20%C3%A2-000-patients
#19
REVIEW
Matthias Totzeck, Raluca Ileana Mincu, Tienush Rassaf
BACKGROUND: The monoclonal antibody bevacizumab effectively inhibits angiogenesis in several types of cancers by blocking vascular endothelial growth factor. However, life-threatening cardiovascular adverse effects could limit its use and may warrant specific follow-up strategies. METHODS AND RESULTS: We systematically searched MEDLINE, Cochrane, EMBASE, and Web of Science for randomized controlled trials published until November 2016 that assessed patients with cancer treated with or without bevacizumab in addition to standard chemotherapy...
August 10, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/28862319/breakthroughs-in-modern-cancer-therapy-and-elusive-cardiotoxicity-critical-research-practice-gaps-challenges-and-insights
#20
REVIEW
Ping-Pin Zheng, Jin Li, Johan M Kros
To date, five cancer treatment modalities have been defined. The three traditional modalities of cancer treatment are surgery, radiotherapy, and conventional chemotherapy, and the two modern modalities include molecularly targeted therapy (the fourth modality) and immunotherapy (the fifth modality). The cardiotoxicity associated with conventional chemotherapy and radiotherapy is well known. Similar adverse cardiac events are resurging with the fourth modality. Aside from the conventional and newer targeted agents, even the most newly developed, immune-based therapeutic modalities of anticancer treatment (the fifth modality), e...
September 1, 2017: Medicinal Research Reviews
keyword
keyword
50
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"